Clinical trials: Caffeine
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Fit-One: A Trial Evaluating the Effect of One Drop and Fitbit on Diabetes and Pre-diabetes Outcomes
The Fit-One trial involves three prospective, randomized waitlist-controlled studies. These studies evaluate the effects of One Drop's digital therapeutics solution with and without Fitbit devices on the social cognitive…
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, PreDiabetes
- Trial name
- Fit-One (NCT03459573)
- Testing
- One Drop | Experts On Track, One Drop | Experts On Call, One Drop | Experts Revive
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Chandra Osborn, PhD, MPH
Healthy
Effects of ElevATP on Body Composition and Athletic Performance
This study will examine the effects of supplemental ElevATP with or without a blend of extended-release caffeine and B vitamins for changes in body composition, athletic performance, and hematology over a 12 week intervention…
- Trial name
- NCT02819219
- Testing
- Supplemental, Exercise Intervention
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- MusclePharm Sports Science Institute
Advanced Solid Tumors, Excluding Breast Cancer
Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors
This is a multi-center, open-label, phase I study to assess the effects of dovitinib (TKI258) on the pharmacokinetics of a cocktail of caffeine, diclofenac, omeprazole and midazolam in patients with advanced solid tumors…
- Trial name
- NCT01596647
- Testing
- caffeine, diclofenac, omeprazole
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Novartis Pharmaceuticals
Pharmacokinetics of Dextromethorphan, Pharmacokinetics of Caffeine
A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer
This study evaluates how once daily enzalutamide affects the metabolism of caffeine and dextromethorphan in men with prostate cancer by measuring concentrations of these drugs and their metabolites in plasma.
- Conditions
- Pharmacokinetics of Dextromethorphan, Pharmacokinetics of Caffeine, Prostate Cancer
- Trial name
- NCT02225093
- Testing
- Caffeine, Dextromethorphan, Enzalutamide
- Where
- Moldova
- Volunteers
- 12 people
- Sponsor
- Astellas Pharma Europe B.V.
Chemotherapy-induced Nausea and Vomiting
An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects
The objective of this Open Label Study is to evaluate effects of Rolapitant IV solution, and its metabolite, on the pharmacokinetics (PK) of the P-gp substrate (digoxin), the BCRP substrate (sulfasalazine), and multiple…
- Trial name
- NCT02434861
- Testing
- Rolapitant, Digoxin, Sulfasalazine
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Tesaro, Inc.
Healthy
A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates
The purpose of this study is to assess the effects of single and multiple once daily doses of 50 milligram (mg) of JNJ-54861911 on pharmacokinetics (PK) (study of the way a drug enters and leaves the blood and tissues over time)…
- Trial name
- NCT02211079
- Testing
- JNJ-54861911, Caffeine, Midazolam
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
Study to Evaluate the Effect of Multiple Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Warfarin, Omeprazole, Caffeine, and Dextromethorphan in Healthy Male Volunteers
The study aimed to investigate the effect of BIRT 2584 XX and its metabolite BI 610100 on the Pharmacokinetics (PK) of five probe substrates for cytochrome P450 isozymes.
- Trial name
- NCT02256813
- Testing
- BIRT 2584 XX, Warfarin sodium, Omeprazole
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pain, Postoperative
Study to Find Out the Optimal Dose of Caffeine in the Combination Tablet of Naproxen Sodium and Caffeine in Patients Experiencing Moderate to Severe Pain After Having Wisdom Teeth Removed
The researchers in this study wanted to find out the optimal dose of Caffeine in the combination tablet of Naproxen Sodium and Caffeine that works in patients experiencing moderate to severe pain after having wisdom teeth…
- Trial name
- NCT04132336
- Testing
- Naproxen sodium/Caffeine (BAY2880376), Naproxen sodium (Aleve), Caffeine
- Where
- United States
- Volunteers
- 193 people
- Sponsor
- Bayer
Metabolism, Alzheimer's Disease
Drug Interaction Study Between AZD3480 and Cytochrome P450
The purpose of the study is to evaluate if AZD3480 inhibits Cytochrome P450 1A2, 2C19, 3A4, 2C8, 2B6 and UGT1A1 activity.
- Trial name
- Cocktail (NCT00692510)
- Testing
- AZD3480, Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)
- Where
- Sweden
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Refractive Ametropia, Astigmatism
1-Week Dispensing Evaluation of REVIVE™ Toric Soft Contact Lenses
Experienced soft contact lens wearing subjects were enrolled in this 1-week, post-market, bilateral, repeated measures, dispensing study.
- Trial name
- NCT06053736
- Testing
- REVIVE Toric Soft Contact Lenses
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Cold
Study Comparing Coristina® D to Resfenol® in the Symptomatic Treatment of Common Cold
The primary objective of this study is to evaluate the non-inferiority of Coristina® d in the symptomatic treatment of the common cold compared to Resfenol® comparator.
- Trial name
- NCT02735070
- Testing
- Resfenol, Coristina d
- Volunteers
- 366 people
- Sponsor
- Brainfarma Industria Química e Farmacêutica S/A
Drug Interaction
A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers
This is a single-centre, open-label, fixed-sequence trial to evaluate the impact of C21 on the exposure of CYP1A2, CYP2C9, CYP3A4 and P-gp substrates in healthy volunteers.
- Trial name
- NCT05830799
- Testing
- Drug Drug Interaction
- Where
- Sweden
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Vicore Pharma AB
Myopia
Evaluation of Short Term Use of Experimental Eye Drops BHVI2, 0.02% Atropine and BHVI2 Plus 0.02% Atropine Eye Drops
To assess the one-month ocular effects of nightly application of experimental BHVI2 and 0.02% atropine eye drops either alone or in combination, in children aged between 6 to 13 years old with myopia and randomized to use of…
- Trial name
- NCT03690414
- Testing
- Experimental BHVI2, Atropine sulfate 0.02% eye drops, Combination eye drops
- Where
- Vietnam
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Hai Yen Eye Care
Normal Controls
Nutrient-Fortified Beverage Study
The objective of this study is to assess the effects of nutrient-fortified beverage on mental energy in healthy human subjects.
- Trial name
- NCT02103192
- Testing
- Anti-Oxidant Drink
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Metabolic Syndrome, Obesity
Pharmacodynamics and Pharmacokinetics of 3 New Developed Coated Glucose Beads in 20 Obese Healthy Subjects
This single-dose, randomized, open label, five-treatment, five-period, five-sequence crossover study was performed to assess pharmacodynamics (PD) and pharmacokinetics (PK) of three new developed coated Glucose beads formulations…
- Trial name
- NCT05713773
- Testing
- coated beads glucose (8 g) and caffeine anhydrous, coated beads glucose (8 g), uncoated beads glucose (8 g) and caffeine anhydrous
- Where
- Romania
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Aphaia Pharma US LLC
Epilepsy
Generalized Seizure Detection And Alerting In The EMU With The Empatica Embrace Watch And Smartphone-Based Alert System
To demonstrate safety and effectiveness of the Embrace device in identifying convulsive seizures (CS) and notifying a caregiver during patient hospitalization at an epilepsy monitoring unit (EMU).
- Trial name
- NCT03207685
- Testing
- Additional Seizure Monitoring
- Where
- 2 sites in United States, Italy
- Volunteers
- 100 people
- Sponsor
- Empatica, Inc.
Rheumatoid Arthritis
Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin
Drug-drug interaction study in healthy men and women not of childbearing potential. Assess the effect of BMS-986195 on the pharmacokinetics of methotrexate, caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and…
- Trial name
- NCT03131973
- Testing
- BMS-986195, Methotrexate, Leucovorin
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Pharyngitis
A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis
The purposes of this study is to demonstrate the analgesic efficacy of flurbiprofen 8.75 mg lozenge compared to its vehicle lozenge and to demonstrate the safety of the flurbiprofen lozenge throughout the course of treating sore…
- Trial name
- NCT01048866
- Testing
- flurbiprofen, acetaminophen 650mg
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- Reckitt Benckiser LLC
Drug-Interactions
Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates
This is a single center, open-label, fixed sequence Phase 1, drug-drug interaction (DDI) study in healthy subjects.
- Trial name
- NCT04764851
- Testing
- ecopipam HCl ~2mg/kg/day, Cohort 1 Probe Cocktail, Cohort 2 Probe Cocktail
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Emalex Biosciences Inc.
Steatohepatitis, Nonalcoholic, Osteo Arthritis
DDI Study of ECC0509 With Metformin, Midazolam, and Caffeine
This is a Phase 1, open-label, 2-part, fixed-sequence, single-center, two-period, drug-drug interaction trial in healthy adult participants to determine if ECC0509 administration at steady state affects the pharmacokinetics (PK)…
- Trial name
- NCT07873229
- Testing
- ECC0509, Metformin, Caffeine
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eccogene